{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T04:28:20Z","timestamp":1789964900469,"version":"4.0.1"},"reference-count":58,"publisher":"Impact Journals, LLC","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,4,18]]},"DOI":"10.18632\/oncotarget.15215","type":"journal-article","created":{"date-parts":[[2017,2,15]],"date-time":"2017-02-15T19:17:50Z","timestamp":1487186270000},"page":"26027-26040","source":"Crossref","is-referenced-by-count":38,"title":["The CRISPR\/Cas9 system efficiently reverts the tumorigenic ability of <i>BCR\/ABL in vitro<\/i> and in a xenograft model of chronic myeloid leukemia"],"prefix":"10.18632","volume":"8","author":[{"given":"Ignacio","family":"Garc\u00eda-Tu\u00f1\u00f3n","sequence":"first","affiliation":[{"name":"Unidad de Diagn\u00f3stico Molecular y Celular del C\u00e1ncer, Centro de Investigaci\u00f3n del C\u00e1ncer-IBMCC (USAL-CSIC), Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Hern\u00e1ndez-S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Unidad de Diagn\u00f3stico Molecular y Celular del C\u00e1ncer, Centro de Investigaci\u00f3n del C\u00e1ncer-IBMCC (USAL-CSIC), Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Ordo\u00f1ez","sequence":"additional","affiliation":[{"name":"Unidad de Diagn\u00f3stico Molecular y Celular del C\u00e1ncer, Centro de Investigaci\u00f3n del C\u00e1ncer-IBMCC (USAL-CSIC), Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Alonso-P\u00e9rez","sequence":"additional","affiliation":[{"name":"Unidad de Diagn\u00f3stico Molecular y Celular del C\u00e1ncer, Centro de Investigaci\u00f3n del C\u00e1ncer-IBMCC (USAL-CSIC), Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"\u00c1lamo-Quijada","sequence":"additional","affiliation":[{"name":"Unidad de Diagn\u00f3stico Molecular y Celular del C\u00e1ncer, Centro de Investigaci\u00f3n del C\u00e1ncer-IBMCC (USAL-CSIC), Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocio","family":"Benito","sequence":"additional","affiliation":[{"name":"Unidad de Diagn\u00f3stico Molecular y Celular del C\u00e1ncer, Centro de Investigaci\u00f3n del C\u00e1ncer-IBMCC (USAL-CSIC), Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Guerrero","sequence":"additional","affiliation":[{"name":"IBSAL, Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca, Salamanca, Spain"},{"name":"Instituto Biolog\u00eda Molecular y Celular del C\u00e1ncer (USAL\/CSIC), Salamanca, Spain"},{"name":"Departamento de Medicina, Universidad de Salamanca, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas Mar\u00eda","family":"Hern\u00e1ndez-Rivas","sequence":"additional","affiliation":[{"name":"Unidad de Diagn\u00f3stico Molecular y Celular del C\u00e1ncer, Centro de Investigaci\u00f3n del C\u00e1ncer-IBMCC (USAL-CSIC), Salamanca, Spain"},{"name":"IBSAL, Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca, Salamanca, Spain"},{"name":"Servicio de Hematolog\u00eda, Hospital Universitario de Salamanca, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"S\u00e1nchez-Mart\u00edn","sequence":"additional","affiliation":[{"name":"IBSAL, Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca, Salamanca, Spain"},{"name":"Servicio de Transg\u00e9nesis, Nucleus, Universidad de Salamanca, Salamanca, Spain"},{"name":"Departamento de Medicina, Universidad de Salamanca, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2017,2,9]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Kantarjian","year":"1999","journal-title":"The New England journal of medicine"},{"key":"2","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Melo","year":"2000","journal-title":"Blood"},{"key":"3","doi-asserted-by":"crossref","first-page":"819","DOI":"10.7326\/0003-4819-138-10-200305200-00010","article-title":"Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics","volume":"138","author":"Talpaz","year":"2003","journal-title":"Annals of internal medicine"},{"key":"4","doi-asserted-by":"crossref","first-page":"re6","DOI":"10.1126\/scisignal.3139re6","article-title":"ABL tyrosine kinases: evolution of function, regulation, and specificity","volume":"3","author":"Colicelli","year":"2010","journal-title":"Sci Signal"},{"key":"5","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1038\/leu.2015.168","article-title":"BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase","volume":"29","author":"Hochhaus","year":"2015","journal-title":"Leukemia"},{"key":"6","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Sawyers","year":"2001","journal-title":"Science"},{"key":"7","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia","volume":"110","author":"Deininger","year":"2007","journal-title":"Blood"},{"key":"8","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1177\/2040620712468289","article-title":"Management of imatinib-resistant patients with chronic myeloid leukemia","volume":"4","author":"Jabbour","year":"2013","journal-title":"Ther Adv Hematol"},{"key":"9","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.clml.2013.05.012","article-title":"A critical review of trials of first-line BCR-ABL inhibitor treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase","volume":"13","author":"Lipton","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1093\/nar\/gkt071","article-title":"A comprehensive approach to zinc-finger recombinase customization enables genomic targeting in human cells","volume":"41","author":"Barbas","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"11","doi-asserted-by":"crossref","first-page":"11163","DOI":"10.1093\/nar\/gks875","article-title":"Chimeric TALE recombinases with programmable DNA sequence specificity","volume":"40","author":"Barbas","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"12","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.tibtech.2013.04.004","article-title":"ZFN, TALEN, and CRISPR\/Cas-based methods for genome engineering","volume":"31","author":"Barbas","year":"2013","journal-title":"Trends Biotechnol"},{"key":"13","doi-asserted-by":"crossref","first-page":"19","DOI":"10.32607\/20758251-2014-6-3-19-40","article-title":"TALEN and CRISPR\/Cas Genome Editing Systems: Tools of Discovery","volume":"6","author":"Zakian","year":"2014","journal-title":"Acta Naturae"},{"key":"14","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1126\/science.1231143","article-title":"Multiplex genome engineering using CRISPR\/Cas systems","volume":"339","author":"Zhang","year":"2013","journal-title":"Science"},{"key":"15","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.cell.2014.05.010","article-title":"Development and applications of CRISPR-Cas9 for genome engineering","volume":"157","author":"Zhang","year":"2014","journal-title":"Cell"},{"key":"16","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s12033-014-9771-z","article-title":"Applications of TALENs and CRISPR\/Cas9 in human cells and their potentials for gene therapy","volume":"56","author":"Chen","year":"2014","journal-title":"Mol Biotechnol"},{"key":"17","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/nature14982","article-title":"Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex","volume":"517","author":"Zhang","year":"2015","journal-title":"Nature"},{"key":"18","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.1246172","article-title":"Genome-scale CRISPR-Cas9 knockout screening in human cells","volume":"343","author":"Zhang","year":"2014","journal-title":"Science"},{"key":"19","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.stem.2013.11.002","article-title":"Functional repair of CFTR by CRISPR\/Cas9 in intestinal stem cell organoids of cystic fibrosis patients","volume":"13","author":"Clevers","year":"2013","journal-title":"Cell Stem Cell"},{"key":"20","doi-asserted-by":"publisher","first-page":"44061","DOI":"10.18632\/oncotarget.6392","article-title":"ASXL1 mutation correction by CRISPR\/Cas9 restores gene function in leukemia cells and increases survival in mouse xenografts","volume":"6","author":"Fulga","year":"2015","journal-title":"Oncotarget"},{"key":"21","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1038\/mt.2016.148","article-title":"CRISPR\/Cas9-Mediated Correction of the Sickle Mutation in Human CD34+ cells","volume":"24","author":"Campo-Fernandez","year":"2016","journal-title":"Mol Ther"},{"key":"22","doi-asserted-by":"crossref","first-page":"477","DOI":"10.15252\/emmm.201506039","article-title":"CRISPR\/Cas9-mediated somatic correction of a novel coagulator factor IX gene mutation ameliorates hemophilia in mouse","volume":"8","author":"Hu","year":"2016","journal-title":"EMBO Mol Med"},{"key":"23","doi-asserted-by":"crossref","first-page":"3964","DOI":"10.1038\/ncomms4964","article-title":"Engineering human tumour-associated chromosomal translocations with the RNA-guided CRISPR-Cas9 system","volume":"5","author":"Rodriguez-Perales","year":"2014","journal-title":"Nat Commun"},{"key":"24","article-title":"Generation of the Fip1l1-Pdgfra fusion gene using CRISPR\/Cas genome editing","author":"Cools","year":"2016","journal-title":"Leukemia"},{"key":"25","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nature13902","article-title":"engineering of oncogenic chromosomal rearrangements with the CRISPR\/Cas9 system","volume":"516","author":"Ventura","year":"2014","journal-title":"Nature"},{"key":"26","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/bjh.14297","article-title":"CRISPR-Cas9 technology and its application in haematological disorders","volume":"175","author":"McCarty","year":"2016","journal-title":"Br J Haematol"},{"key":"27","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.yexcr.2005.12.007","article-title":"Characterization of p87C3G, a novel, truncated C3G isoform that is overexpressed in chronic myeloid leukemia and interacts with Bcr-Abl","volume":"312","author":"Guerrero","year":"2006","journal-title":"Experimental cell research"},{"key":"28","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/309126a0","article-title":"Interleukin-3 supports growth of mouse pre-B-cell clones","volume":"309","author":"McKearn","year":"1984","journal-title":"Nature"},{"key":"29","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/nbt.3026","article-title":"Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation","volume":"32","author":"Root","year":"2014","journal-title":"Nat Biotechnol"},{"key":"30","doi-asserted-by":"crossref","first-page":"726","DOI":"10.4161\/rna.24321","article-title":"The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems","volume":"10","author":"Charpentier","year":"2013","journal-title":"RNA Biol"},{"key":"31","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1099\/mic.0.023960-0","article-title":"Short motif sequences determine the targets of the prokaryotic CRISPR defence system","volume":"155","author":"Almendros","year":"2009","journal-title":"Microbiology"},{"key":"32","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1128\/JB.01412-07","article-title":"Phage response to CRISPR-encoded resistance in Streptococcus thermophilus","volume":"190","author":"Moineau","year":"2008","journal-title":"J Bacteriol"},{"key":"33","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/nature20134","article-title":"CRISPR\/Cas9 beta-globin gene targeting in human haematopoietic stem cells","volume":"539","author":"Narla","year":"2016","journal-title":"Nature"},{"key":"34","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/BF01630378","article-title":"The minute chromosome (Phl) in chronic granulocytic leukemia","volume":"8","author":"Nowell","year":"1962","journal-title":"Blut"},{"key":"35","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"36","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood.V88.7.2375.bloodjournal8872375","article-title":"The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype","volume":"88","author":"Melo","year":"1996","journal-title":"Blood"},{"key":"37","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1126\/science.3460176","article-title":"The chronic myelogenous leukemia-specific P210 protein is the product of the bcr\/abl hybrid gene","volume":"233","author":"Baltimore","year":"1986","journal-title":"Science"},{"key":"38","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0092-8674(85)80053-2","article-title":"Il-3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes","volume":"41","author":"Steinmetz","year":"1985","journal-title":"Cell"},{"key":"39","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood.V83.8.2038.2038","article-title":"Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia","volume":"83","author":"Jones","year":"1994","journal-title":"Blood"},{"key":"40","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1111\/febs.13760","article-title":"Off-target effects of engineered nucleases","volume":"283","author":"Yee","year":"2016","journal-title":"FEBS J"},{"key":"41","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.stem.2014.06.011","article-title":"Whole-genome sequencing analysis reveals high specificity of CRISPR\/Cas9 and TALEN-based genome editing in human iPSCs","volume":"15","author":"Ye","year":"2014","journal-title":"Cell Stem Cell"},{"key":"42","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.stem.2014.06.016","article-title":"Targeted gene correction minimally impacts whole-genome mutational load in human-disease-specific induced pluripotent stem cell clones","volume":"15","author":"Soligalla","year":"2014","journal-title":"Cell Stem Cell"},{"key":"43","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.stem.2014.04.020","article-title":"Low incidence of off-target mutations in individual CRISPR-Cas9 and TALEN targeted human stem cell clones detected by whole-genome sequencing","volume":"15","author":"Musunuru","year":"2014","journal-title":"Cell Stem Cell"},{"key":"44","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1006\/jmbi.1996.0779","article-title":"Regulation of Bcl-2 gene expression by BCR-ABL is mediated by Ras","volume":"267","author":"Martin-Zanca","year":"1997","journal-title":"J Mol Biol"},{"key":"45","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.hoc.2004.03.008","article-title":"Biology of chronic myelogenous leukemia\u2014signaling pathways of initiation and transformation","volume":"18","author":"Deininger","year":"2004","journal-title":"Hematol Oncol Clin North Am"},{"key":"46","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1182\/blood.V97.7.2084","article-title":"BCR-ABL down-regulates the DNA repair protein DNA-PKcs","volume":"97","author":"Bourhis","year":"2001","journal-title":"Blood"},{"key":"47","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1038\/leu.2008.78","article-title":"BCR\/ABL promotes accumulation of chromosomal aberrations induced by oxidative and genotoxic stress","volume":"22","author":"Skorski","year":"2008","journal-title":"Leukemia"},{"key":"48","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1053\/j.seminhematol.2010.06.008","article-title":"Stem cell transplant for chronic myeloid leukemia in the imatinib era","volume":"47","author":"Radich","year":"2010","journal-title":"Semin Hematol"},{"key":"49","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1089\/hum.2015.074","article-title":"Delivery and Specificity of CRISPR-Cas9 Genome Editing Technologies for Human Gene Therapy","volume":"26","author":"Bumcrot","year":"2015","journal-title":"Human gene therapy"},{"key":"50","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.celrep.2016.09.092","article-title":"Highly Efficient Genome Editing of Murine and Human Hematopoietic Progenitor Cells by CRISPR\/Cas9","volume":"17","author":"Nakada","year":"2016","journal-title":"Cell reports"},{"key":"51","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1101\/gr.171322.113","article-title":"Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins","volume":"24","author":"Kim","year":"2014","journal-title":"Genome research"},{"key":"52","doi-asserted-by":"crossref","first-page":"9312","DOI":"10.1073\/pnas.85.23.9312","article-title":"Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr\/abl protein","volume":"85","author":"Baltimore","year":"1988","journal-title":"Proc Natl Acad Sci USA"},{"key":"53","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nbt0496-499","article-title":"Efficient control of gene expression by single step integration of the tetracycline system in transgenic mice","volume":"14","author":"Bluethmann","year":"1996","journal-title":"Nat Biotechnol"},{"key":"54","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1038\/sj.onc.1209968","article-title":"Sustained leukaemic phenotype after inactivation of BCR-ABLp190 in mice","volume":"26","author":"Sanchez-Garcia","year":"2007","journal-title":"Oncogene"},{"key":"55","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/nmeth.3047","article-title":"Improved vectors and genome-wide libraries for CRISPR screening","volume":"11","author":"Zhang","year":"2014","journal-title":"Nat Methods"},{"key":"56","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nbt.2951","article-title":"Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing","volume":"32","author":"Ebert","year":"2014","journal-title":"Nat Biotechnol"},{"key":"57","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/nature03959","article-title":"Genome sequencing in microfabricated high-density picolitre reactors","volume":"437","author":"Fierro","year":"2005","journal-title":"Nature"},{"key":"58","doi-asserted-by":"publisher","first-page":"18875","DOI":"10.18632\/oncotarget.4303","article-title":"The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin","volume":"6","author":"Teodosio","year":"2015","journal-title":"Oncotarget"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.15215","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T13:45:59Z","timestamp":1596721559000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.15215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,9]]},"references-count":58,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2017,4,18]]}},"alternative-id":["15215","28212528"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.15215","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,9]]}}}